Skip to main content
SpringerLink
Log in

Relapse Rate Following Azathioprine Withdrawal in Maintaining Remission for Crohn’s Disease: A Meta-Analysis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The duration of use of azathioprine (Aza) and 6-mercaptopurine (6-MP) for maintaining remission for Crohn’s disease is debatable.

Aim

To examine whether Aza/6-MP can be safely withdrawn in patients with Crohn’s disease who have been in remission.

Methods

The following databases were searched: MEDLINE (1950–September 2010), EMBASE (1980–September 2010), CINHAL (1981–September 2010), PubMed (1950–September 2010), and the Cochrane Central Register of Controlled Trials (CENTRAL). Randomised controlled and cohort studies comparing azathioprine continuation versus placebo or no treatment were eligible for inclusion. Primary outcomes were relapse rate after discontinuation of Aza/6-MP at 6, 12, and 18 months, and 5 and 10 years.

Results

Five studies, with 256 patients and 168 controls, met the inclusion criteria. Stopping azathioprine/6-MP was found to significantly increase the risk of relapse at 6, 12, and 18 months with pooled odds ratios of 0.22 (95% CI 0.09–0.53), 0.25 (95% CI 0.11–0.56), and 0.35 (95% CI 0.21–0.6), respectively. Two trials examined relapse rate at 5 years with pooled OR 0.53 (95% CI 0.13–2.21). No trials looking at relapse rates beyond 5 years were identified.

Conclusions

There is a clear benefit of continuing Aza/6-MP for at least 18 months to maintain remission for Crohn’s disease patients who established remission. There is not enough evidence to provide clear guidance on whether or not to continue Aza/6-MP treatment beyond 18 months. Well-designed randomised controlled trials addressing this issue are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shanahan E, Bernstien CN. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol. 2009;25:301–305.

    Article  PubMed  Google Scholar 

  2. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112–124.

    PubMed  Google Scholar 

  3. Prefontaine E, Sutherland LR, MacDonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s Disease (Review). Cochrane Database of Systematic Reviews. 2009 Art No: CD000067.

  4. Carter MJ, Lobo MJ, Travis SPL. British society of gastroenterology guidelines for the management of inflammatory Bowel disease in adults. Gut. 2003;53:v1–v16.

    Article  Google Scholar 

  5. British National Formulary 60 BMJ Group and Pharmaceutical Press. 2010. http://bnf.org/bnf/bnf/current/. Accessed Sep 17 2010.

  6. Bouknik Y, Lemann M, Mary JY, et al. Long-term follow up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215–219.

    Article  Google Scholar 

  7. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: A high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80–85.

    Article  PubMed  Google Scholar 

  8. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Therap. 2010;32:1365–2036.

    Article  Google Scholar 

  9. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248–3253.

    Article  PubMed  CAS  Google Scholar 

  10. O’Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet. 1978;2:955–957.

    Article  PubMed  Google Scholar 

  11. Nyman M, Hansson I, Eriksson S. Long term immunosuppressive treatment in Crohn’s disease. Scan J Gastroenterol. 1985;20:1197–1203.

    Article  CAS  Google Scholar 

  12. Korelitz BI, Adler DI, Mendelsohn RA, et al. Long term experience with 6-Mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol. 1993;88:1198–1205.

    PubMed  CAS  Google Scholar 

  13. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated Feb 2008). The Cochrane Collaboration. 2008.

  14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  PubMed  CAS  Google Scholar 

  15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–560.

    Article  Google Scholar 

  16. Daya D. Funnel plots and publication bias—work in progress? Evidence-based Obs Gyn. 2006;8:71–72.

    Article  Google Scholar 

  17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–634.

    CAS  Google Scholar 

  18. Peters JL, Sutton AJ, Jones D, et al. Comparison of two methods to detect publication bias in meta-analysis. J Am Med Ass. 2006;295:676–680.

    Article  CAS  Google Scholar 

  19. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol. 1999;94:3254–3257.

    Article  PubMed  CAS  Google Scholar 

  20. Lemann M, Mary J-Y, Colombel J-F, et al. A randomised, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–1818.

    Article  PubMed  CAS  Google Scholar 

  21. Vilien M, Dahlerup JF, Munck LK, et al. Randomised controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: Increased relapse rate the following year. Alimen Pharmacol Therap. 2004;19:1147–1152.

    Article  CAS  Google Scholar 

  22. Sokol H, Seksik P, Nion-Larmurier I, et al. Current smoking, not duration of remission, delays Crohn’s disease relapse following azathioprine withdrawal. Inflamm Bowel Dis. 2010;16:362–363.

    PubMed  Google Scholar 

  23. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology. 1990;99:1347–1351.

    PubMed  CAS  Google Scholar 

  24. Fraser AG, Orchard TR, Jewell DP, et al. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 years review. Gut. 2002;50:485–489.

    Article  PubMed  CAS  Google Scholar 

  25. McGovern D, Travis S. Thiopurine therapy: When to start and when to stop. Europ J Gastroenterol Hepatol. 2003;15:219–223.

    Article  CAS  Google Scholar 

  26. Holtmann M, Krummenaeur F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: A European multicenter study in 1176 patients. Dig Dis Sci. 2006;51:1516–1524.

    Article  PubMed  CAS  Google Scholar 

  27. Pica R, Avallone EV, Cassieri C, et al. Optimal duration of maintenance treatment with azathioprine in patients with inflammatory bowel disease. Dig Liver Dis. 2010;42S:S61–S192.

    Google Scholar 

  28. Angelucci E, Cesarini M, Gentile P, et al. Azathioprine withdrawal in Crohn’s disease: A never-ending story? Dig Liver Dis. 2010;42S:S61–S192.

    Google Scholar 

  29. Candy S, Wright J, Gerber M, et al. A double-blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn’s disease. Gut. 1995;37:674–678.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr H Sokol and Dr P Seksik for providing supplementary data for “Sokol H, Seksik P, Nion-Larmurier I et al. Current smoking, not duration of remission, delays Crohn’s disease relapse following azathioprine withdrawal. Inflammatory Bowel Disease 2010; 16: 362–363.”

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Paediatric Gastroenterology, Hepatology and Nutrition, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool, L12 2AP, UK

    Helen French, A. Mark Dalzell, Ramesh Srinivasan & Wael El-Matary

  2. Institute of Child Health, University of Liverpool, Liverpool, UK

    Wael El-Matary

Authors
  1. Helen French
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Mark Dalzell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramesh Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wael El-Matary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wael El-Matary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

French, H., Mark Dalzell, A., Srinivasan, R. et al. Relapse Rate Following Azathioprine Withdrawal in Maintaining Remission for Crohn’s Disease: A Meta-Analysis. Dig Dis Sci 56, 1929–1936 (2011). https://doi.org/10.1007/s10620-011-1671-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1671-5

Keywords

Search

Navigation